BOCA RATON, Fla., Nov. 16, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing
Investors attending the conferences who wish to meet with management for a one-on-one meeting should notify their appropriate contact.
For more information and registration, please visit the conference websites: Evercore ISI and Drexel Hamilton.
About Sensus Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
Investor Relations:Jeffrey Goldberger / Allison Soss KCSA Strategic CommunicationsPhone: 212-896-1249 / 212-896-1267Email: email@example.com / firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sensus-healthcare-to-participate-in-two-upcoming-investor-conferences-on-november-30th-and-december-1st-300363952.html
SOURCE Sensus Healthcare
Subscribe to our Free Newsletters!
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...View All